A TGF ‐β signaling‐related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response
CNS Neuroscience & Therapeutics · 2024-04 · 30 (4)
DOI: 10.1111/cns.14489 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 18.10.2023. Verfasst von Wei-Wei Duan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Glioma, RNA, Long Noncoding, Transforming Growth Factor beta. Die Arbeit wurde bisher 162-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hunan Provincial Natural Science Foundation of China, Hunan Provincial Health Committee Foundation of China.
Abstract (Originalsprache)
Aims
The dysregulation of TGF‐β signaling is a crucial pathophysiological process in tumorigenesis and progression. LncRNAs have diverse biological functions and are significant participants in the regulation of tumor signaling pathways. However, the clinical value of lncRNAs related to TGF‐β signaling in glioma is currently unclear.
Methods
Data on glioma's RNA‐seq transcriptome, somatic mutation, DNA methylation data, and clinicopathological information were derived from the CGGA and TCGA databases. A prognostic lncRNA signature was constructed by Cox and LASSO regression analyses. TIMER2.0 database was utilized to deduce immune infiltration characteristics. “ELMER v.2” was used to reconstruct TF‐methylation‐gene regulatory network. Immunotherapy and chemotherapy response predictions were implemented by the TIDE algorithm and GDSC database, respectively. In vitro and in vivo experiments were conducted to verify the results and clarify the regulatory mechanism of lncRNA.
Results
In glioma, a TGF‐β signaling‐related 15‐lncRNA signature was constructed, including AC010173.1, HOXA‐AS2, AC074286.1, AL592424.1, DRAIC, HOXC13‐AS, AC007938.1, AC010729.1, AC013472.3, AC093895.1, AC131097.4, AL606970.4, HOXC‐AS1, AGAP2‐AS1, and AC002456.1. This signature proved to be a reliable prognostic tool, with high risk indicating an unfavorable prognosis and being linked to malignant clinicopathological and genomic mutation traits. Risk levels were associated with different immune infiltration landscapes, where high risk was indicative of high levels of macrophage infiltration. In addition, high risk also suggested better immunotherapy and chemotherapy response. cg05987823 was an important methylation site in glioma progression, and AP‐1 transcription factor family participated in the regulation of signature lncRNA expression. AGAP2‐AS1 knockdown in in vitro and in vivo experiments inhibited the proliferation, migration, and invasion of glioma cells, as well as the growth of glioma, by downregulating the expression levels of NF‐κB and ERK 1/2 in the TGF‐β signaling pathway.
Conclusions
A prognostic lncRNA signature of TGF‐β signaling was established in glioma, which can be used for prognostic judgment, immune infiltration status inference, and immunotherapy response prediction. AGAP2‐AS1 plays an important role in glioma progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Experiment Center of Medical Innovation, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
- MRC Centre for Regenerative Medicine, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
- Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
ORCID-Profile: Wei-Wei Duan, Quan Cheng
Förderung
- National Natural Science Foundation of China
- Hunan Provincial Natural Science Foundation of China
- Hunan Provincial Health Committee Foundation of China
- Science Foundation of AMHT Group
Zitieren
APA
Duan, W. W., Yang, L. T., Liu, J., Dai, Z. Y., Wang, Z. Y., Zhang, H., Zhang, X., Liang, X. S., Luo, P., Zhang, J., Liu, Z. Q., Zhang, N., Mo, H. Y., Qu, C. R., Xia, Z. W., & Cheng, Q. (2024). A TGF ‐β signaling‐related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response. CNS Neuroscience & Therapeutics, 30(4). https://doi.org/10.1111/cns.14489
Vancouver
Duan WW, Yang LT, Liu J, Dai ZY, Wang ZY, Zhang H, et al. A TGF ‐β signaling‐related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response. CNS Neuroscience & Therapeutics. 2024;30(4). doi:10.1111/cns.14489
BibTeX
@article{Duan2024,
author = {Duan, Wei-Wei and Yang, Li-Ting and Liu, Jian and Dai, Zi-Yu and Wang, Ze-Yu and Zhang, Hao and Zhang, Xun and Liang, Xi-Song and Luo, Peng and Zhang, Jian and Liu, Zao-Qu and Zhang, Nan and Mo, Hao-Yang and Qu, Chun-Run and Xia, Zhi-Wei and Cheng, Quan},
title = {A TGF ‐β signaling‐related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
volume = {30},
number = {4},
doi = {10.1111/cns.14489}
}
EUVIMED